Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASMET: S-1 plus metformin vs S-1 alone as adjuvant therapy after resection of pancreatic cancer in patients with diabetes
jRCTs031180270Phase 2Completed
- Sponsor
- National Hospital Organization
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic cancer (PC) and type 2 diabetes mellitus (T2DM) comparing S-1 + metformin with S-1 alone (non-metformin diabetes therapy) (2 arms). Primary endpoint: 2-year overall survival rate. Started Feb 2018; status: completed.
02
Drugs
tegafurmetformin
03
Conditions
pancreatic cancer (PC)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180270.